ICON plc Ordinary Shares ICLR
i
Market datapartial · fetched 2026-11-12T15:18:15.687Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T15:17:15.316484314Z
FundamentalsAlpha Vantage · unavailable
ICON plc Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 213.10 | 57.8% | 9.1% | 182.81 | 62.7% | 8.2% |
| 25Δ | 208.78 | 54.0% | 7.2% | 186.33 | 59.1% | 6.7% |
| 30Δ | 206.56 | 54.9% | 6.5% | 189.35 | 55.1% | 5.4% |
| 35Δ | 204.33 | 55.7% | 5.7% | 191.64 | 53.3% | 4.6% |
| 40Δ | 202.11 | 56.6% | 5.0% | 193.74 | 52.0% | 3.9% |
| 45Δ | 199.89 | 57.4% | 4.3% | 195.69 | 50.5% | 3.3% |
| 50Δ | 197.76 | 58.1% | 3.7% | 197.45 | 48.7% | 2.7% |
| 55Δ | 195.63 | 58.8% | 3.2% | 199.20 | 46.9% | 2.2% |
| 60Δ | 193.29 | 60.7% | 2.8% | 201.17 | 46.3% | 1.8% |
| 65Δ | 190.84 | 63.1% | 2.4% | 203.32 | 46.7% | 1.5% |
| 70Δ | 188.41 | 63.1% | 2.0% | 205.48 | 47.1% | 1.2% |
| 75Δ | 185.97 | 62.0% | 1.5% | 207.63 | 47.5% | 1.0% |
| 80Δ | 182.84 | 62.9% | 1.2% | 209.78 | 48.0% | 0.7% |
20Δ
- Pseudo strike
- 213.10
- IV
- 57.8%
- B/E move
- 9.1%
- Pseudo strike
- 182.81
- IV
- 62.7%
- B/E move
- 8.2%
25Δ
- Pseudo strike
- 208.78
- IV
- 54.0%
- B/E move
- 7.2%
- Pseudo strike
- 186.33
- IV
- 59.1%
- B/E move
- 6.7%
30Δ
- Pseudo strike
- 206.56
- IV
- 54.9%
- B/E move
- 6.5%
- Pseudo strike
- 189.35
- IV
- 55.1%
- B/E move
- 5.4%
35Δ
- Pseudo strike
- 204.33
- IV
- 55.7%
- B/E move
- 5.7%
- Pseudo strike
- 191.64
- IV
- 53.3%
- B/E move
- 4.6%
40Δ
- Pseudo strike
- 202.11
- IV
- 56.6%
- B/E move
- 5.0%
- Pseudo strike
- 193.74
- IV
- 52.0%
- B/E move
- 3.9%
45Δ
- Pseudo strike
- 199.89
- IV
- 57.4%
- B/E move
- 4.3%
- Pseudo strike
- 195.69
- IV
- 50.5%
- B/E move
- 3.3%
50Δ
- Pseudo strike
- 197.76
- IV
- 58.1%
- B/E move
- 3.7%
- Pseudo strike
- 197.45
- IV
- 48.7%
- B/E move
- 2.7%
55Δ
- Pseudo strike
- 195.63
- IV
- 58.8%
- B/E move
- 3.2%
- Pseudo strike
- 199.20
- IV
- 46.9%
- B/E move
- 2.2%
60Δ
- Pseudo strike
- 193.29
- IV
- 60.7%
- B/E move
- 2.8%
- Pseudo strike
- 201.17
- IV
- 46.3%
- B/E move
- 1.8%
65Δ
- Pseudo strike
- 190.84
- IV
- 63.1%
- B/E move
- 2.4%
- Pseudo strike
- 203.32
- IV
- 46.7%
- B/E move
- 1.5%
70Δ
- Pseudo strike
- 188.41
- IV
- 63.1%
- B/E move
- 2.0%
- Pseudo strike
- 205.48
- IV
- 47.1%
- B/E move
- 1.2%
75Δ
- Pseudo strike
- 185.97
- IV
- 62.0%
- B/E move
- 1.5%
- Pseudo strike
- 207.63
- IV
- 47.5%
- B/E move
- 1.0%
80Δ
- Pseudo strike
- 182.84
- IV
- 62.9%
- B/E move
- 1.2%
- Pseudo strike
- 209.78
- IV
- 48.0%
- B/E move
- 0.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 42.13% | |
| 43.98% | |
| 48.20% | |
| 47.42% | |
| 47.82% | |
| 44.97% | |
| 45.85% | |
| 46.12% | |
| 44.81% | |
| 45.06% | |
| 45.48% | |
| 46.26% | |
| 47.35% | |
| 46.48% | |
| 46.01% | |
| 45.81% | |
| 48.59% | |
| 49.15% | |
| 47.98% | |
| 46.61% | |
| 49.17% | |
| 50.40% | |
| 50.98% | |
| 51.74% | |
| 48.32% | |
| 47.83% | |
| 47.64% | |
| 48.23% | |
| 50.36% | |
| 48.55% | |
| 50.56% | |
| 49.36% | |
| 49.76% | |
| 50.73% | |
| 49.61% | |
| 50.08% | |
| 51.37% | |
| 51.41% | |
| 49.62% | |
| 49.41% | |
| 51.81% | |
| 52.25% | |
| 56.64% | |
| 54.28% | |
| 54.45% | |
| 54.52% | |
| 53.98% | |
| 54.95% | |
| 54.56% | |
| 56.05% | |
| 53.54% | |
| 44.85% | |
| 44.44% | |
| 47.07% |
Diagnostics & Research
IDXX
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal…
More →ILMN
Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and…
More →IMDX
OncoCyte Corporation is a precision diagnostics company in the United States and internationally. The company is headquartered in Irvine, California.
More →IQV
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is…
More →LH
Laboratory Corporation of America Holdings, more commonly known as Labcorp, is an American company headquartered in Burlington, North Carolina. It operates one of the largest…
More →MEDP
Description unavailable
More →